Biotech · Public company · Emeryville, CA, US

BioAge Labs, Inc.

Ticker BIOA · SEC CIK 0001709941

Track this companyFree. Adds BioAge Labs, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials42 recruiting or active

Pipeline programs7From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline7

Anti-VEGFPhase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
BGE-175Phase 2 · Covid19ClinicalTrials.gov · fetched Nov 12, 2026
Oral Azelaprag (BGE-105)Phase 2 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
Oral BGE-102Phase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
Oral BGE-102Phase 2 · Obesity and Cardiovascular RiskClinicalTrials.gov · fetched Nov 12, 2026
ShamPhase 2 · Diabetic Macular Edema (DME)ClinicalTrials.gov · fetched Nov 12, 2026
TirzepatidePhase 2 · ObesityClinicalTrials.gov · fetched Nov 12, 2026

A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular EdemaPHASE2 · RECRUITING · started Aug 21, 2026ClinicalTrials.gov NCT07812090 · fetched Nov 12, 2026
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk FactorsPHASE2 · ACTIVE_NOT_RECRUITING · started Jun 11, 2026ClinicalTrials.gov NCT07656727 · fetched Nov 12, 2026
Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and OverPHASE2 · TERMINATED · started Jun 27, 2024ClinicalTrials.gov NCT06515418 · fetched Nov 12, 2026
Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory FailurePHASE2 · TERMINATED · started Mar 18, 2021ClinicalTrials.gov NCT04705597 · fetched Nov 12, 2026